-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Overall survival (OS) after diagnosis of acute myeloid leukemia (AML) in adults has improved
over the past three decades.
This improvement was most pronounced in patients aged 50-70 years, and was associated with, but not necessarily caused
, an increase in the proportion of patients aged 50-70 who received intensive chemotherapy and subsequently referred to allogeneic hematopoietic cell transplantation (HCT).
Especially after
the introduction of non-myeloablative conditioning.
At the same time, allogeneic HCT regimens and supportive care have improved
.
However, population-based studies
have been lacking in recent years.
Therefore, a team of researchers investigated trends in OS, cure rates, and other outcomes after allogeneic HCT treatment for AML from 2000 to 2020
in a Danish population-based cohort study.
They studied all adult (> 18-year-old) patients
who received their first allogeneic HCT treatment for AML in Denmark between 2000 and 2020.
Until 2009, all transplants were performed
at Rig Hopitale, University Hospital of Copenhagen.
Since then, Aarhus University Hospital has transplanted patients
from western Denmark.
Allogeneic HCT is indicated for consolidation therapy
in patients with a first complete response (CR) or secondary AML with moderate or adverse cytogenetic risk, in patients with second CR regardless of cytogenetic risk, and in selected patients with AML who have failed one induction.
A total of 659 patients were included, equivalent to 13%
of the 5241 adults diagnosed with AML in Denmark between 2000 and 2020.
The number of transplants increased over time, with 239 (36%) patients
transplanted from 2016 to 2020.
The median follow-up was 7.
5 years and the median OS was 7.
9 years
.
The estimated biennial and quinquennial operating systems are 66 per cent and 57 per cent
, respectively.
The main causes of death were relapse (54% of deaths) and infection (13% of deaths).
Patients with poor cytogenetics and intermediate cytogenetics had two-year OS of 53% and 68%, respectively; Unadjusted estimates
of OS based on HCT conditioning intensity, donor type, and disease status.
OS varied widely between 2000 and 2020 (p-value for overall HCT calendar year impact = 0.
02).
The unadjusted biennial operating system was 75 per cent in 2000, 59 per cent in 2010 and 71 per cent
in 2020.
Five-year operating systems show a similar trend
.
The trend towards OS was most pronounced in patients receiving myeloablative pretreatment, but there was no statistically significant interaction between HCT calendar years and conditioning regimens (p = 0.
32).
Figure 1: Estimated two-year overall survival (OS) after allogeneic hematopoietic cell transplantation (HCT) for acute myeloid leukemia (AML) based on transplant calendar year
Original source:
Gjaerde LK, Jakobsen LH, Juhl-Christensen C, Olesen G, Petruskevicius I, Severinsen MT, Marcher CW, Theilgaard-Mönch K, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Sengeløv H.
Trends in survival and cure after allogeneic haematopoietic cell transplantation for acute myeloid leukaemia from 2000 to 2020: A Danish population-based cohort study.
Br J Haematol.
2022 Oct 20.
doi: 10.
1111/bjh.
18511.
Epub ahead of print.
PMID: 36263998.
